Latest Conference Articles | OncLive

Latest Conference Articles

Regorafenib Showed Modest Activity in Ewing Sarcoma

Regorafenib Showed Modest Activity in Ewing Sarcoma

September 20th 2020, 8:45pm

ESMO Congress

Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.

Updated Findings Show Olaparib Prolongs OS in Men with mCRPC

Updated Findings Show Olaparib Prolongs OS in Men with mCRPC

September 20th 2020, 8:20pm

ESMO Congress

Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

Pralsetinib Active in RET-Mutant Advanced Medullary Thyroid Cancer

September 20th 2020, 7:38pm

ESMO Congress

Potent and durable clinical activity was shown with pralsetinib as treatment of patients with RET-mutant advanced medullary thyroid cancer, regardless of the line of therapy.

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

September 20th 2020, 6:21pm

ESMO Congress

The combination of amivantamab and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib-resistant patients with advanced EGFR-mutant non–small cell lung cancer.

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

September 20th 2020, 6:14pm

ESMO Congress

Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.

DART Molecule MGD019 Displays Monotherapy Efficacy in Heavily Pretreated Solid Tumors

DART Molecule MGD019 Displays Monotherapy Efficacy in Heavily Pretreated Solid Tumors

September 20th 2020, 6:00pm

ESMO Congress

An acceptable safety profile coupled with pharmacokinetic and pharmacodynamic data for the DART molecule MGD019 were reported during the European Society for Medical Oncology Virtual Congress 2020 from results of a first-in-human study.

Entrectinib Shows Intracranial Response in NTRK+ Tumors and CNS Metastases

Entrectinib Shows Intracranial Response in NTRK+ Tumors and CNS Metastases

September 20th 2020, 5:58pm

Entrectinib demonstrated durable intracranial activity in a small subset of patients with NTRK fusion–positive solid tumors and baseline central nervous system metastases.

Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer

Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer

September 20th 2020, 5:44pm

ESMO Congress

The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone

Immune-Related Biomarkers Linked With OS Benefits of Frontline Maintenance Avelumab in Advanced Urothelial Carcinoma

Immune-Related Biomarkers Linked With OS Benefits of Frontline Maintenance Avelumab in Advanced Urothelial Carcinoma

September 20th 2020, 5:15pm

ESMO Congress

Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.

QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial

QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial

September 20th 2020, 5:00pm

ESMO Congress

Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.

x